Logo image of BIOA

BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

NASDAQ:BIOA - US09077V1008 - Common Stock

4.93 USD
+0.13 (+2.71%)
Last: 8/29/2025, 8:00:01 PM
4.9 USD
-0.03 (-0.61%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, BIOA scores 3 out of 10 in our fundamental rating. BIOA was compared to 193 industry peers in the Pharmaceuticals industry. While BIOA has a great health rating, there are worries on its profitability. BIOA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIOA has reported negative net income.
BIOA had a negative operating cash flow in the past year.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.53%, BIOA is in line with its industry, outperforming 57.51% of the companies in the same industry.
BIOA has a better Return On Equity (-26.81%) than 62.18% of its industry peers.
Industry RankSector Rank
ROA -24.53%
ROE -26.81%
ROIC N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOA has been increased compared to 1 year ago.
BIOA has a better debt/assets ratio than last year.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

BIOA has an Altman-Z score of 2.64. This is not the best score and indicates that BIOA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.64, BIOA is doing good in the industry, outperforming 69.95% of the companies in the same industry.
BIOA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.64
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

BIOA has a Current Ratio of 13.21. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BIOA (13.21) is better than 87.56% of its industry peers.
BIOA has a Quick Ratio of 13.21. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.21, BIOA belongs to the best of the industry, outperforming 87.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.21
Quick Ratio 13.21
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BIOA have decreased by -6.13% in the last year.
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIOA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.52% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y72.78%
EPS Next 2Y29.98%
EPS Next 3Y19.52%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 1M 2M 3M 4M
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

BIOA's earnings are expected to grow with 19.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.98%
EPS Next 3Y19.52%

More info and screens

0

5. Dividend

5.1 Amount

BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAGE LABS INC

NASDAQ:BIOA (8/29/2025, 8:00:01 PM)

After market: 4.9 -0.03 (-0.61%)

4.93

+0.13 (+2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-07 2025-11-07
Inst Owners64.03%
Inst Owner Change2.49%
Ins Owners3.64%
Ins Owner Change0%
Market Cap176.74M
Analysts46.67
Price Target4.76 (-3.45%)
Short Float %7.1%
Short Ratio12.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.44%
Min EPS beat(2)-22.35%
Max EPS beat(2)33.23%
EPS beat(4)2
Avg EPS beat(4)-198.03%
Min EPS beat(4)-810.1%
Max EPS beat(4)33.23%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-17.65%
EPS NQ rev (1m)-13.04%
EPS NQ rev (3m)21.23%
EPS NY rev (1m)-13.53%
EPS NY rev (3m)-11.93%
Revenue NQ rev (1m)34.05%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)84.5%
Revenue NY rev (3m)66.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.75
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-9.63
EYN/A
EPS(NY)-2.56
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.11
BVpS8.22
TBVpS8.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.53%
ROE -26.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.29%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 508.89%
Cap/Sales 23.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.21
Quick Ratio 13.21
Altman-Z 2.64
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.66%
EPS Next Y72.78%
EPS Next 2Y29.98%
EPS Next 3Y19.52%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.31%
EBIT Next 3Y-13.29%
EBIT Next 5YN/A
FCF growth 1Y-38.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.9%
OCF growth 3YN/A
OCF growth 5YN/A